PROGRAMME PORTO CANCER MEETING

02 MAY 2019

09.00 Welcome Session, Manuel Sobrinho-Simões, i3S/ Ipatimup & Mário Barbosa, i3S

Session 1: Microbiome in Cancer

Chairs: Fátima Carneiro, CHSJ and Céu Figueiredo, i3S

9.15-9.45 Role of the gut microbiome in causing, detecting and treating colorectal cancer
Paul O’Toole, School of Microbiology, University College Cork, Ireland

9.45-10.15  Interplay between immune contexture and gut microbiota in human colorectal cancer
Giandomenica Iezzi,  Ente Ospedaliero Cantonale and Università della Svizzera Italiana, Switzerland

10.15-10.45 Coffee-break

10.45-11.15 Gut microbiota, can we improve the outcome of cancer immunotherapy
Meriem Messaoudene, Centre de Recherche du Centre Hospitalier de l’Universite de Montreal, Canada

11.15-11.30 SELECTED TALK: Gastric cancer is characterized by a dysbiotic microbiome
Rui Ferreira, i3S – Instituto de Investigação e Inovação em Saúde/ Ipatimup, Portugal

SPECIAL SESSION: A tribute to socitey 

Chair: José Carlos Machado, i3S

11.30-12.00 How the contributions from society have improved the clinical management and molecular understanding of paediatric brain tumours         

Jorge Lima, i3S – Instituto de Investigação e Inovação em Saúde, Portugal &

Maria João Gil da Costa, Department of Paediatric Oncology, Centro Hospitalar de São João, Portugal

12.00-13.00 Lunch

13.00-14.30 Speed Talks | Auditorium Corino de Andrade

Chairs: Patrícia Oliveira, i3S and Hugo Caires, i3S

Session 2: Tumour Microenvironment

Chairs: Rui Henrique, IPO-Porto and Raquel Seruca, i3S

14.30-15.00 The crosstalk between stem-like cancer cells and the tumor microenvironment
Joana Paredes, i3S – Instituto de Inovação em Saúde / Ipatimup, Portugal

15.00-15.30 Metabolic interactions in chronic lymphocytic leukemia
Dimitrios Mougiakakos, Department of Medicine 5 – Hematology and Clinical Oncology, University of Erlangen, Germany

15.30-16.00 Coffee-break

16.00-16.30 Neoadjuvant chemotherapy elicits a pro-metastatic cascade through extracellular vesicles
Ioanna Keklikoglou, Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Switzerland

16.30-16.45 SELECTED TALK: Pancreatic Cancer Stem Cells Coordinate an Organized Exosomes Communication Network that Dysregulates the Hippo Pathway Contributing to Pancreatic Cancer Progression
Carolina Ruivo, i3S – Instituto de Investigação e Inovação em Saúde and Instituto de Ciências Biomédicas de Abel Salazar, Portugal

20.00 Meeting Dinner

03 MAY 2019

Session 3: Inflammation and Cancer

Chairs: Guilherme Macedo, CHSJ and José Carlos Machado, i3S

9.00-9.30 “Inflammation and homeostasis” to understand “Inflammation and cancer”
Francisco Real, Spanish National Cancer Research Centre / Universitat Pompeu Fabra, Spain

09.30-10.00Immune-metabolism in Liver Cancer and Cancer Cachexia
Erwin Wagner, Medical University Vienna, Austria

10.00-10.30 Coffee Break

10.30-11.00 On the role of innate and adaptive immune cells in fatty liver disease and subsequent liver cancer
Mathias Heikenwälder,Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany

11.00-11.15 SELECTED TALK: Crosstalk of signaling hubs and chronic inflammation in human tumorigenesis
Carla Lopes, Instituto Gulbenkian de Ciência, Portugal

11.15-12.30 Speed Talks | Auditorium Corino de Andrade

Chairs: Sérgia Velho, i3S and Stefan Mereiter, i3S

12.30-14.00 Lunch and Poster viewing

Session 4: Immunotherapy

Chairs: Júlio Oliveira, IPO-Porto and Sónia Melo, i3S

14.00-14.30 The Exosomes in Immune Suppression and Tumor Progression
Wei Guo, Department of Biology, School of Arts & Sciences, University of Pennsylvania, USA

14.30-15.00 Neoadjuvant immunotherapy – the pathway to biomarker identification and personalized therapy
Christian Blank, Netherlands Cancer Institute, the Netherlands

15.00-15.30 Coffee-break

16.00-16.30 Signal Finding Platform trials: optimizing drug development
Pablo Martinez Rodriguez, Medimmune, LLC, USA

16.30-16.45 SELECTED TALK: Homologous recombination deficiency in metastatic gastric cancer
Nuno Sousa, IPO-Porto, Portugal

Adjourn